0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > ICOS

ICOS

Brief Information

Name:Inducible T-cell costimulator
Target Synonym:Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ICS-R52H9-ELISA
 ICOS ELISA

Immobilized Rat ICOS / CD278 (C137S, C138S), His Tag (Cat. No. ICS-R52H9) at 5 μg/mL (100 μL/well) can bind Mouse B7-H2, Fc Tag (Cat. No. B72-M5258) with a linear range of 2-39 ng/mL (QC tested).

ICS-H52Ha-MALS-HPLC
ICOS MALS images

The purity of Human ICOS Protein, His Tag (Cat. No. ICS-H52Ha) is more than 90% and the molecular weight of this protein is around 52-62 kDa verified by SEC-MALS.

Synonym Name

ICOS,CD278,AILIM,Inducible T-cell costimulator

Background

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vopratelimab JTX-2011 Phase 2 Clinical Jounce Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Izuralimab XmAb-23104; XmAb-104 Phase 2 Clinical Xencor Inc Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms Details
Feladilimab GSK-609; GSK-3359609 Phase 2 Clinical Glaxosmithkline Plc Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma Details
Alomfilimab KY-1044 Phase 2 Clinical Kymab Ltd Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Acazicolcept ALPN-101 Phase 2 Clinical Alpine Immune Sciences Inc Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation Details
MEDI-570 Phase 1 Clinical Japan Tobacco (Hong Kong) Ltd Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Mycosis Fungoides Details
Anti-ICOS (Bristol Myers Squibb) BMS-986226 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
Vopratelimab JTX-2011 Phase 2 Clinical Jounce Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Izuralimab XmAb-23104; XmAb-104 Phase 2 Clinical Xencor Inc Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms Details
Feladilimab GSK-609; GSK-3359609 Phase 2 Clinical Glaxosmithkline Plc Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma Details
Alomfilimab KY-1044 Phase 2 Clinical Kymab Ltd Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Acazicolcept ALPN-101 Phase 2 Clinical Alpine Immune Sciences Inc Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation Details
MEDI-570 Phase 1 Clinical Japan Tobacco (Hong Kong) Ltd Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Mycosis Fungoides Details
Anti-ICOS (Bristol Myers Squibb) BMS-986226 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message